% | $
Quotes you view appear here for quick access.

Agenus Inc. Message Board

  • eiretekk eiretekk Sep 5, 2013 10:10 AM Flag

    Don't bury the body yet

    "In line with the Inependent Data Monitoring Committee's (IDMC) unanimous recommendation, GSK will continue the DERMA trial until the second co-primary endpoint is assessed. This endpoint, DFS in the gene signature positive sub-population, is designed to identify a subset of MAGE-A3 positive patients that may benefit from the treatment. Results from this analysis are expected in 2015. Until then, GSK will remain blinded to all safety and efficacy data. "

5.55+0.170(+3.16%)Jul 29 4:00 PMEDT